A 58-year-old male client with HFrEF taking spironolactone 2… | MyMerci
Medical EmergenciesPA
Question
A 58-year-old male client with HFrEF taking spironolactone 25 mg orally daily for 8 weeks reports new painful breast enlargement and tenderness. Recent labs show K+ 4.4 mEq/L (normal), and the EF remains improved at 40%. Which response by the nurse is most appropriate?
1"Painful breast enlargement is a known anti-androgen effect of spironolactone; the provider may switch you to eplerenone, which is a selective aldosterone antagonist with much less gynecomastia."✓ Correct answer
2"Breast changes like this can occur when fluid overload is present; we will need to intensify your diuretic regimen and possibly add a loop diuretic to manage this symptom and monitor your potassium levels closely."
3"It is important to discontinue spironolactone due to this side effect; your provider may consider switching you to an ACE inhibitor or digoxin to control your symptoms and reduce the risk of hospitalization."
4"This is a separate issue likely not related to your heart medication; you should schedule an appointment with your primary care provider for a breast examination and possible mammogram to rule out malignancy."
Explanation
Spironolactone — non-selective aldosterone antagonism and gynecomastia Spironolactone is a potassium-sparing aldosterone receptor antagonist used in HFrEF, resistant HTN, primary hyperaldosteronism, cirrhotic ascites, hirsutism, and acne. It is non-selective — it also blocks androgen and progesterone receptors and inhibits androgen synthesis. Anti-androgen effects produce gynecomastia (10%·dose-dependent), breast tenderness, decreased libido, and erectile dysfunction in men, and menstrual irregularity in women. Standard management when this becomes intolerable: switch to eplerenone, a selective aldosterone antagonist with similar HF/HTN benefit but markedly fewer anti-androgen side effects. Patient should not stop the medication independently; abrupt discontinuation in HFrEF can lead to decompensation. Other key teaching: monitor K+ (especially with ACEi/ARB co-prescription), avoid K+ supplements and salt substitutes containing K+, and report new muscle weakness/cramps/palpitations.
In-depth explanation
Clinical reasoning summary Spironolactone — non-selective aldosterone antagonism and gynecomastia Spironolactone is a potassium-sparing aldosterone receptor antagonist used in HFrEF, resistant HTN, primary hyperaldosteronism, cirrhotic ascites, hirsutism, and acne. It is non-selective — it also blocks androgen and progesterone receptors and inhibits androgen synthesis. Anti-androgen effects produce gynecomastia (10%·dose-dependent), breast tenderness, decreased libido, and erectile dysfunction in men, and menstrual irregularity in women. Standard management when this becomes intolerable: switch to eplerenone, a selective aldosterone antagonist with similar HF/HTN benefit but markedly fewer anti-androgen side effects. Patient should not stop the medication independently; abrupt discontinuation in HFrEF can lead to decompensation. Other key teaching: monitor K+ (especially with ACEi/ARB co-prescription), avoid K+ supplements and salt substitutes containing K+, and report new muscle weakness/cramps/palpitations.